Targeted Dendrimer-Minocycline Nanotherapy for Brain Disorders

Dr. Devinder Maheshwari[1], Sukhdeep Singh[2]
[1] *Assistant Professor, University College of Pharmacy, Guru Kashi University*
[2] *M.Pharm Scholar, University College of Pharmacy, Guru Kashi University*

***Abstract*—Brain disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, stroke, traumatic brain injury, and glioblastoma remain challenging to treat because of the limited ability of therapeutic agents to cross the blood-brain barrier (BBB) and achieve targeted drug delivery. Dendrimer-based nanotechnology has emerged as a promising strategy to overcome these limitations by enabling site-specific drug delivery with improved bioavailability and reduced systemic toxicity. Among various therapeutic agents, minocycline, a second-generation tetracycline antibiotic, has demonstrated significant neuroprotective, anti-inflammatory, antioxidant, and anti-apoptotic properties. However, its clinical application is constrained by poor brain targeting and dose-related adverse effects. Targeted dendrimer-minocycline nanotherapy offers an innovative approach by conjugating minocycline with dendrimer nanoparticles, facilitating selective accumulation in activated microglia and inflamed brain tissues. In our study, we developed a dendrimer–minocycline conjugate designed to improve the targeted delivery of minocycline to injured CNS tissue. This rationally designed dendrimer–minocycline nanomedicine integrates the pharmacological potential of minocycline with the neuroinflammation-targeting properties of hydroxyl PAMAM dendrimers.**

I. INTRODUCTION

Neurological diseases such as Alzheimer's disease, Parkinson's disease, traumatic brain injury (TBI), stroke, brain tumors, and multiple sclerosis affect hundreds of millions of people globally and impose substantial social and economic burdens [1]. Despite advances in molecular neuroscience and drug discovery, therapeutic success in CNS disorders remains limited, primarily due to the inability of most drugs to reach their intended targets within the brain [2]. The BBB strictly regulates molecular trafficking between the bloodstream and the brain, allowing only small, lipophilic molecules or those transported via specific carrier-mediated mechanisms to enter the CNS [3]. Traditional approaches to bypass or disrupt the BBB, including intrathecal injection, osmotic disruption, and high systemic dosing, are invasive, risky, and often associated with systemic toxicity. Consequently, there is a compelling need for innovative drug delivery platforms that can safely and selectively transport therapeutics across the BBB. Nanomedicine has emerged as a promising solution, enabling the engineering of nanoscale carriers that can interact with biological barriers in a controlled manner [4]. Among the various nanocarriers investigated, dendrimers offer unparalleled structural precision and functional versatility, making them highly attractive candidates for targeted brain drug delivery [5].

II. BLOOD BRAIN BARRIER: STRUCTURE AND FUNCTION

2.1 Blood Brain Barrier – Structure

Endothelial cells forming the BBB are characterized by minimal fenestrations, low pinocytic activity, and the presence of tight junction proteins such as claudins, occludins, and zonula occludens. In addition, the BBB expresses a range of efflux transporters, including P-glycoprotein and breast cancer resistance protein, which actively remove xenobiotics from the brain. The BBB is a highly specialized, multicellular interface that separates the cerebral circulation from the brain parenchyma. Its barrier function arises from the coordinated organization of several structural elements, including brain microvascular endothelial cells (BMECs), tight junctions, pericytes, astrocytic end-feet, and the

basement membrane (BM). Together, these components regulate molecular trafficking, preserve central nervous system (CNS) homeostasis, and protect the brain from circulating toxins, pathogens, and inflammatory mediators.

BMECs form the principal cellular layer of the BBB and possess several highly specialized features that distinguish them from peripheral endothelial cells [6-8]. In contrast to endothelial cells in most systemic tissues, BMECs are sealed by highly restrictive tight junctions, exhibit minimal rates of transcytosis and pinocytosis, and lack fenestrations, collectively limiting paracellular and transcellular transport. The luminal surface of BMECs is coated with a glycocalyx-rich layer consisting of proteoglycans, glycoproteins, and glycosaminoglycans, which not only enhances barrier function but also acts as a mechanosensory interface responsive to blood flow dynamics [9]. Importantly, the specialized phenotype of BMECs is maintained through continuous bidirectional signaling with surrounding pericytes and astrocytes, emphasizing the cooperative and integrated nature of the neurovascular unit (NVU).



Figure 1 :- Anatomical structure of the blood–brain barrier (BBB) [10]

Tight junctions (TJs) are the hallmark structural feature of the BBB and are composed of integral membrane proteins, including claudins—especially claudin-5, claudin-3, and claudin-12—along with occludin and junctional adhesion molecules (JAMs), which are linked intracellularly to scaffolding proteins such as zonula occludens (ZO-1, ZO-2, and ZO-3). Among these, claudin-5 is the predominant claudin expressed in brain endothelial cells and plays a central role in maintaining BBB selectivity.

Pericytes are specialized mural cells located within the vascular basement membrane (BM), where they maintain close physical and functional interactions with endothelial cells through peg-and-socket contacts and gap junction–like structures. Astrocytes contribute to BBB organization through highly specialized cellular extensions known as end-feet, which envelop nearly 99% of the cerebral microvasculature and form the outermost cellular interface of the barrier. These astrocytic end-feet are enriched with aquaporin-4 (AQP4) water channels and inwardly rectifying potassium channels (Kir4.1), enabling precise regulation of water transport, ion balance, and extracellular potassium buffering within the CNS.

2.2 Blood Brain Barrier - Function

The BBB is a dynamic and complex interface that plays a critical role in maintaining CNS homeostasis. Occludin is involved in regulating barrier integrity and in intracellular signaling pathways, whereas JAMs participate in tight junction organization and facilitate leukocyte trafficking during inflammatory responses. The intracellular ZO proteins connect

transmembrane TJ components to the actin cytoskeleton, providing structural stability.

BBB actively prevent neurotoxin accumulation. Precise ionic and neurotransmitter homeostasis is maintained through active transport mechanisms (e.g., Na^+/K^+-ATPase, excitatory amino acid transporters) that ensure a stable neuronal microenvironment. Highly selective carrier-mediated and receptor-mediated transport systems for nutrient delivery (e.g., glucose, macromolecules). It is a controlled neuroimmune interface that regulates immune surveillance via specific endothelial adhesion molecules.

Pericytes, specialized mural cells, perform diverse and essential functions within the neurovascular unit (NVU), including regulation of capillary tone and cerebral blood flow, secretion of extracellular matrix components for BM maintenance, and production of trophic factors that support endothelial cell survival and BBB maturation. Pericytes are also critical for maintaining BBB integrity by suppressing endothelial transcytosis and promoting proper tight junction organization.

III. NANOMEDICINE APPROACHES FOR BRAIN DRUG DELIVERY

Nanomedicine offers a compelling strategy to overcome the limitations imposed by the BBB by enabling the rational design of carriers that interact favorably with biological barriers [11]. By controlling particle size, surface charge, and surface chemistry, nanocarriers can be engineered to prolong circulation time, evade immune clearance, and selectively accumulate in the brain. In addition to enhancing brain delivery, nanomedicine platforms enable multifunctional therapeutic strategies. Nano carriers can simultaneously deliver drugs and imaging agents, allowing for real-time monitoring of biodistribution and therapeutic response. They can also be designed for controlled or stimuli-responsive drug release, which is particularly advantageous in the CNS, where sustained therapeutic exposure is often required.

3.1 Targeting Strategies in Nanomedicine

Active and passive targeting are the two foundational paradigms that guide the design of nanomedicines for drug delivery, imaging, and diagnostic applications Together, they define how nanoscale systems interact with biological barriers, circulate within the body, and ultimately accumulate at sites of disease



Figure 2: Passive vs active targeting.

3.1.1 Passive Targeting

Passive targeting refers to the preferential accumulation of nanomedicines at diseased sites as a consequence of pathophysiological features rather than specific molecular recognition. The most widely studied example is the enhanced permeability and retention effect observed in many solid tumors. Beyond oncology, passive targeting also plays a significant role in inflammatory and infectious diseases. Inflammation is associated with endothelial activation, increased vascular permeability, and recruitment of immune cells, all of which facilitate nanoparticle accumulation.

3.1.2 Active Targeting: Ligand-Mediated Specificity and Cellular Uptake

This strategy involves functionalizing the surface of nanocarriers with ligands capable of selectively binding to molecular targets expressed on diseased cells or within pathological microenvironments. These ligands include small molecules, peptides, antibodies and antibody fragments, aptamers, carbohydrates, and other biomolecular motifs. The molecular targets are typically receptors, antigens, or transporters that are overexpressed or selectively upregulated in disease, such as growth factor receptors on cancer cells, adhesion molecules on inflamed endothelium, or scavenger receptors on activated immune cells. The principal advantage of active targeting lies in its ability to enhance cellular association, internalization, and intracellular delivery of therapeutic payloads. While passive targeting primarily dictates tissue-level accumulation, active targeting operates at the cellular and subcellular levels.

3.2 Nanoparticles based brain drug delivery systems

3.2.1 Lipid-Based Nanoparticles for Brain Drug Delivery.

Liposomes, which are spherical vesicles composed of phospholipid bilayers enclosing an aqueous core, have been widely investigated due to their biocompatibility and ability to encapsulate both hydrophilic and hydrophobic drugs. The physicochemical properties of liposomes can be tuned by modifying lipid composition, cholesterol content, and surface chemistry, allowing for optimization of stability and drug release profiles. Surface modification with polyethylene glycol has been shown to reduce opsonization and prolong circulation time, thereby increasing the likelihood of BBB interaction. Despite these advantages, conventional liposomes often exhibit limited brain accumulation following systemic administration. To address this limitation, ligand-targeted liposomes have been developed to engage receptor-mediated transport pathways at the BBB.

Solid lipid nanoparticles and nanostructured lipid carriers represent more recent developments in lipid-based nanomedicine. These systems are composed of solid or partially solid lipid matrices that offer improved physical stability and higher drug loading capacity compared to conventional liposomes.

3.2.2. Polymeric Nanoparticles

Polymeric nanoparticles have emerged as versatile platforms for brain drug delivery due to their tunable physicochemical properties and biodegradability. Polymers such as poly(lactic-co-glycolic acid), polycaprolactone, and chitosan have been extensively used to fabricate nanoparticles capable of encapsulating a wide range of therapeutic agents.

PLGA nanoparticles, in particular, have been widely studied for the delivery of small molecules, peptides, and nucleic acids to the brain . PEGylation of PLGA nanoparticles reduces protein adsorption and immune recognition, while ligand conjugation enables interaction with specific BBB receptors. Despite these advances, polymeric nanoparticles often exhibit heterogeneous size distributions and limited reproducibility, which can complicate clinical translation.

3.2.3 Dendrimers for Brain Drug Delivery

Dendrimers represent a distinct and highly engineered class of nanocarriers characterized by their monodisperse, tree-like architecture (Figure 3). These macromolecules consist of a central core, multiple generations of branching units, and a dense outer shell of functional groups. Poly(amidoamine) dendrimers are among the most extensively studied dendritic systems for biomedical applications due to their well-defined structure, high water solubility, and synthetic versatility.



Figure 3 ;- Structural representation of dendrimer depicting its components

Studies have shown that neutral or hydroxyl-terminated dendrimers can cross compromised BBB regions associated with neuroinflammation, brain tumors, and traumatic brain injury, while exhibiting minimal uptake in healthy brain tissue.

PAMAM Dendrimers

Poly(amidoamine) (PAMAM) dendrimers are among the earliest and most extensively studied dendritic nanomaterials. They are classically composed of three key structural features: (i) a central core, historically based on ethylenediamine; (ii) repeating branched units containing amide linkages that create a highly defined internal architecture with nanoscale cavities; and (iii) terminal amine groups on the dendrimer surface . Because of their internal cavities and abundant peripheral functional groups, PAMAM dendrimers can encapsulate, complex, or conjugate therapeutic and diagnostic agents, making them attractive platforms for biomedical applications.

PPI Dendrimers

Poly(propyleneimine) (PPI) dendrimers are among the earliest commercially available dendrimers investigated for drug delivery applications. These dendrimers are typically composed of a diaminobutane (DAB) core and repeating propyleneimine branching units that generate a highly branched three-dimensional architecture.

PLL Dendrimers

Poly(L-lysine) (PLL) dendrimers, also known as dendri-grafted poly(L-lysine) (DGL), are dendritic nanostructures constructed from lysine amino acid residues arranged in a highly branched architecture. PLL dendrimers exhibit several favorable biological properties, including enhanced biocompatibility, relatively low cytotoxicity, biodegradability through enzymatic cleavage, and eventual elimination as low-molecular-weight degradation products. These characteristics make PLL dendrimers particularly attractive for biomedical and translational applications.

IV. CARBOSILANE DENDRIMERS

Carbosilane dendrimers are a unique class of dendritic macromolecules characterized by carbon–silicon (C–Si) frameworks that provide highly hydrophobic and thermally stable internal architectures. One of the distinguishing features of carbosilane dendrimers is the low polarity and high bond energy of the C–Si linkage, which contributes to their remarkable chemical stability and pronounced hydrophobicity. These properties make carbosilane dendrimers attractive for applications requiring stable nanostructures and the encapsulation of hydrophobic therapeutic agents.

4.1 Drug Loading Strategies in Dendrimer Nanomedicine

Therapeutic agents can be incorporated into dendrimers through either physical encapsulation within internal cavities or covalent conjugation to surface functional groups. The choice of linker chemistry plays a critical role in determining drug release behavior. Cleavable linkers responsive to pH, enzymatic activity, or redox conditions can be employed to ensure drug release occurs preferentially within diseased brain tissue or specific cellular compartments. These strategies enhance therapeutic efficacy while minimizing systemic toxicity.

4.2 Targeting Strategies for Brain Delivery Using Dendrimers

Targeting strategies for dendrimer-based brain drug delivery can be broadly categorized into passive, active, and cell-specific targeting approaches. Passive targeting exploits the compromised BBB associated with neuroinflammation or injury, allowing dendrimers to preferentially accumulate in affected regions. Active targeting involves conjugation of ligands that interact with receptors expressed on BBB endothelial cells, facilitating receptor-mediated transcytosis.

4.3 Routes of Administration for Nanomedicine-Based Brain Delivery

The route of administration plays a critical role in determining the efficacy of nanomedicine-based brain delivery strategies . Systemic administration via intravenous injection remains the most clinically relevant route but is often limited by rapid clearance and off-target accumulation. Intranasal delivery has gained increasing attention as a non-invasive approach that bypasses the BBB by exploiting direct connections between the nasal cavity and the brain. Intrathecal and intracerebral administration provide direct access to the CNS but are highly invasive and associated with significant clinical risks.

V. AIM

In vitro drug release of dendrimer-minocycline

This aim investigated the release behavior of minocycline from the dendrimer platform under physiologically relevant conditions. Drug release studies were conducted in buffered media and enzyme-containing environments to evaluate the stability of the linker system and its responsiveness toward enzymatic cleavage. The release kinetics provided important insight into the ability of the nanoconjugate to achieve controlled and sustained drug release while minimizing premature drug leakage during systemic circulation.

In Vitro Drug-Release Studies (Minocycline release)

The in vitro release profile of minocycline from the D-mino conjugate was evaluated under two different conditions: (1) physiological conditions using phosphate-buffered saline (PBS, pH 7.4) and (2) enzyme-responsive conditions using citrate buffer (pH 5.5) containing esterase. The conjugate was prepared at a concentration of 1 mg/mL in PBS (4 mL × 3) and citrate buffer (4 mL × 3). Esterase was added to the citrate buffer formulation at 2 equivalents per amide linkage to facilitate enzymatic cleavage. All samples were incubated at 37 °C under continuous stirring, and fresh enzyme was supplemented every 48 h to maintain enzymatic activity throughout the study.

At predetermined time intervals, samples were collected in triplicate. For enzyme-containing samples, methanol was added immediately to quench enzymatic activity and precipitate the protein. The mixtures were subsequently centrifuged at 10,000 rpm for 5 min, and the clear supernatants were carefully collected. The processed samples were stored at −80 °C until further analysis by HPLC.

Results for Aim: In vitro drug release behavior of dendrimer–minocycline

In vitro release studies are expected to demonstrate a sustained and controlled release profile of minocycline from the dendrimer conjugate compared to free drug. The release kinetics are anticipated to be tunable based on the conjugation chemistry and environmental conditions, supporting the potential of the dendrimer system for prolonged therapeutic exposure and reduced burst release.

The dendrimer-minocycline showed stability at extracellular pH conditions (pH 7.4). However, the drug was released from the dendrimer in a sustained way at intracellular conditions (pH 5.5 + esterase). Briefly, in first 50 hours, ~10% drug was released. From 50-200 hours, ~30% drug was released and then stayed constant (Figure 4)



Figure 4 : In vitro drug release studies for dendrimer-minocycline at plasma pH and intracellular pH conditions.

VI. CONCLUSION

The *in vitro* release studies conducted in this work provide critical insight into the release kinetics, conjugate stability, and environmental responsiveness of the dendrimer–drug system. The observed release behavior demonstrates the ability of dendrimer conjugation to modulate minocycline availability over time, potentially overcoming limitations associated with conventional free-drug administration such as rapid clearance, poor tissue selectivity, systemic toxicity, and off-target effects. These findings support the concept that dendrimer-based platforms can serve not only as passive carriers but also as engineered therapeutic systems capable of fine-tuning drug pharmacodynamics and biodistribution.

REFERENCES

[1] Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. Neurology 2019,18 (5), 459-480.

[2] Gribkoff, V. K.; Kaczmarek, L. K., The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes. Neuropharmacology 2017,120, 11-19.

[3] Kaya, M.; Ahishali, B., Basic physiology of the blood-brain barrier in health and disease: a brief overview. Tissue barriers 2021,9 (1), 1840913.

[4] Kazi, R. N. A.; Hasani, I. W.; Khafaga, D. S. R.; Kabba, S.; Farhan, M.; Aatif, M.; Muteeb, G.; Fahim, Y. A., Nanomedicine: The Effective Role of Nanomaterials in Healthcare from Diagnosis to Therapy. Pharmaceutics 2025,17 (8).

[5] Nikzamir, M.; Hanifehpour, Y.; Akbarzadeh, A.; Panahi, Y., Applications of Dendrimers in Nanomedicine and Drug Delivery: A Review. Journal of Inorganic and Organometallic Polymers and Materials 2021,31 (6), 2246-2261.

[6] Lochhead, J. J.; Yang, J.; Ronaldson, P. T.; Davis, T. P., Structure, Function, and Regulation of the Blood-Brain Barrier Tight Junction in Central Nervous System Disorders. Frontiers in physiology 2020,11, 914.

[7] Ronaldson, P. T.; Davis, T. P., Regulation of blood-brain barrier integrity by microglia in health and disease: A therapeutic opportunity. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2020,40 (1_suppl), S6-s24.

[8] Ben-Zvi, A.; Liebner, S., Developmental regulation of barrier- and non-barrier blood vessels in the CNS. Journal of internal medicine 2022,292 (1), 31-46.

[9] Taslimifar, M.; Faltys, M.; Kurtcuoglu, V.; Verrey, F.; Makrides, V., Analysis of L-leucine amino acid transporter species activity and gene expression by human blood brain barrier hCMEC/D3 model reveal potential LAT1, LAT4, B(0)AT2 and y(+)LAT1 functional cooperation. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2022,42 (1), 90-103.

[10] Neumaier, F.; Zlatopolskiy, B. D.; Neumaier, B., Drug Penetration into the Central Nervous System: Pharmacokinetic Concepts and In Vitro Model Systems. Pharmaceutics 2021,13 (10), 1542.

[11] Kulkarni, M.; Patel, K.; Patel, A.; Patel, S.; Desai, J.; Patel, M.; Shah, U.; Patel, A.; Solanki, N., Nanomaterials as drug delivery agents for overcoming the blood-brain barrier: A comprehensive review. Admet & dmpk 2024,12 (1), 63-105.